FoundationOne Liquid is the first and only liquid biopsy test to show prospective clinical utility in a global, registrational trial for patients with newly diagnosed, metastatic non-small cell lung cancer (NSCLC).1

Learn more about FoundationOne Liquid

The Relentless Pursuit of Better CareOptionsInsightsScience

We never give up. We strive to do more for cancer patients - through richer science, deeper insights, and stronger partnerships - providing better cancer care today, and fueling better cancer care tomorrow.

PATIENT INFORMATION HERE

Foundation Medicine, The Molecular Information Company, is connecting physicians and their patients to the latest cancer treatment approaches and making precision medicine a reality for thousands.

Better Care Today

1

Genomic Testing

Comprehensive Genomic Profiling

Our portfolio of genomic tests is the leading platform for comprehensive genomic profiling. We analyze more than 300 genes across the four main classes of genomic alterations to help understand the genomic makeup of a patient's tumor.

2

Molecular Insights

Valuable Insights, Actionable Options

We help match each patient’s unique genomic profile to known targeted therapies, immunotherapies and clinical trials and offer decision support services, financial assistance, and technology solutions to help streamline patient care.

Patient Story

Dealing with cancer is not just dealing with the cancer. It’s treating the whole person.

|

Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test.

Christine Bray

Better Care Tomorrow

3

More Than Numbers

Insights, Not Just Information

Our unique knowledgebase, FoundationCore®, is one of the world's largest cancer genomic databases, with more than 350,000 anonymized patient records, designed to help researchers and biopharma companies advance precision medicine, develop new therapies, and design better trials.

4

Supporting Drug Development

The Preferred Partner to BioPharma

We partner with drug developers throughout each stage of drug research and development, from target discovery to commercial launch. Today, we are working with more than 30 biopharma partners to accelerate new biomarker-driven treatments.

Advancing Cancer Care

Each patient’s cancer informs all those cases that will come in the future.

|

Learn more about our recent Journal of the American Medical Association (JAMA) publication on our clinico-genomic database (CGDB) that demonstrates how real-world clinico-genomic data obtained during the course of routine patient care can yield scientifically and clinically meaningful insights.

Gaurav Singal, MD, Chief Data Officer

Gaurav Singal, MD - Chief Data Officer

Better Care Together

5

Collective Advances

The Power of Collaboration

By sharing our genomic data, we empower researchers on the front lines to generate new connections and insights. Today, we proudly participate in a number of sharing initiatives to accelerate research efforts.

6

Transforming Cancer Care

Cultivating an Ecosystem of Partners

Every insight we gain towards better cancer care is multiplied by a hyper-connected network of physicians, biopharma, researchers, patient advocacy organizations and world-leading medical centers. Together, we are transforming cancer care.

My passion for what we offer at Foundation Medicine stems from my belief that CGP can play a fundamental role of advancing personalized medicine, by amplifying the volume of data we feed into the precision medicine engine and improving the consistency, quality and potential of that data. So, as we approach the San Antonio Breast Cancer Symposium, the leading breast cancer meeting of the year, I wanted to take some time to provide my perspectives on the latest milestone we have reached with one of our oncology partners.

Read the Article

Join Us in the Pursuit of Better

Find out more about genomic testing, learn more about us, or read the latest updates from our blog.

1 LBA81_PR ‘Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: initial results from ALK+ cohort’ will be presented by Shirish Gadgeel during the proffered paper session on Monday, 30 September 2019, 08:30-10:00 CEST in Madrid Auditorium (Hall 2). Annals of Oncology, Volume 30, Supplement 5, October 2019.